Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry by Hare, DJ et al.
1656 Metallomics, 2013, 5, 1656--1662 This journal is c The Royal Society of Chemistry 2013
Cite this: Metallomics,2013,
5, 1656
Profiling the iron, copper and zinc content in primary
neuron and astrocyte cultures by rapid online
quantitative size exclusion chromatography-
inductively coupled plasma-mass spectrometry
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Metals often determine the chemical reactivity of the proteins to which they are bound. Each cell in the
body tightly maintains a unique metalloproteomic profile, mostly dependent on function. This paper
describes an analytical online flow injection quantitative size exclusion chromatography-inductively coupled
plasma-mass spectrometry (SEC-ICP-MS) method, which was applied to profiling the metal-binding proteins
found in primary cultures of neurons and astrocytes. This method can be conducted using similar
amounts of sample to those used for Western blotting (20–150 mg protein), and has a turnaround time
of o15 minutes. Metalloprotein standards for Fe (as ferritin), Cu and Zn (as superoxide dismutase-1)
were used to construct multi-point calibration curves for online quantification of metalloproteins by
SEC-ICP-MS. Homogenates of primary neuron and astrocyte cultures were analysed by SEC-ICP-MS.
Online quantification by external calibration with metalloprotein standards determined the mass of metal
eluting from the column relative to time (as pg s1). Total on-column Fe, Cu and Zn detection limits ranged
from 0.825  0.005 ng to 13.6  0.7 pg. Neurons and astrocytes exhibited distinct metalloprotein profiles,
featuring both ubiquitous and unique metalloprotein species. Separation and detection by SEC-ICP-MS
allows appraisal of these metalloproteins in their native state, and online quantification was achieved
using this relatively simple external calibration process.
Introduction
The brain maintains some of the highest concentrations of
metals in the body.1 Free alkali and alkaline earth metals play
important roles in the transmission of nerve impulses and
signal transduction, whilst transition metals, including Fe, Cu
and Zn mediate a variety of cellular functions by way of their
unique redox chemistry. Concentrations of these metals in the
brain range from 10 to 100 mM, depending on the organelle and
cell type in which they are found,2 and the brain must tightly
regulate the chemical state of these transition metals to ensure
oxidative stress via metal-mediated Fenton and Haber–Weiss-
type chemistry is controlled. Increasing evidence has suggested
improper transition metal metabolism may contribute to
the pathogenesis of various neurological disorders, including
Alzheimer’s and Parkinson’s disease, through generation of
toxic reactive oxygen species by labile metal ions.3
The source of oxidative stress-inducing metal species is a
continuous point of contention with regard to the brain. Fe, Cu
and Zn are distributed throughout the brain in a highly compart-
mentalised manner,4 reflective of the diverse roles metal species
play across the most complex organ in the body. Indeed, metal
distribution is likely to be equally distinct at the cellular level,
both with regard to total metal content and the protein species to
which they are bound.
As such, we set out to examine the distribution of Fe, Cu and
Zn according to the molecular species in two of the major cell
types found throughout the brain: neurons and astrocytes.
Interactions between these cell types govern a huge amount
a The Florey Institute of Neuroscience and Mental Health, The University of
Melbourne, Kenneth Myer Building, 30 Royal Parade, Parkville, Victoria, 3052,
Australia. E-mail: blaine.roberts@florey.edu.au; Tel: +61 3 9035 6635
b Elemental Bio-imaging Facility, University of Technology, Broadway, Sydney,
New South Wales, Australia
c Centre for Neuroscience & Department of Pathology, The University of Melbourne,
Parkville, Victoria, Australia
d Agilent Technologies, Santa Clara, California, USA
e Agilent Technologies, Tokyo, Japan
Received 21st August 2013,























































View Journal  | View Issue
This journal is c The Royal Society of Chemistry 2013 Metallomics, 2013, 5, 1656--1662 1657
of neurophysiological processes, from development to pathology;
yet detailed study of the chemistry surrounding the relationship
of these two integral cells has been somewhat limited by the lack
of suitably sensitive analytical techniques. Rapid improvements
to analytical technology have helped remove a key challenge to
understanding both the nature of brain function and how it is
compromised in disease. Cahoy et al.5 recently applied both
fluorescence-activated cell sorting and GeneChip Array technol-
ogy to profile the transcriptome of neurons, astrocytes and
oligodendrocytes, finding that the genetic characteristics of the
latter two cell types were so markedly diﬀerent that previous
generic classification of them both as ‘glia’ is likely insuﬃcient.
Yang et al.6 used a proteomic approach to characterise the
diversity of chemical species in rat cerebellar neurons and
astrocytes, identifying both concurrent and unique proteins in
both cell types, presented in a reference database. Both studies
identified a range of cellular markers that more distinctly
diﬀerentiate astrocytes and neurons then the traditional glial
fibrillary acidic protein (GFAP) marker.
Thus, there is little doubt that the metalloproteomic profile
of neurons and astrocytes contains unique information regarding
the host cell type. Further, proteins that have been implicated in
neurological diseases have also been suggested to play roles in
metal metabolism, such as the Zn and Cu interactions with prion
protein (PrP)7 and proposed role of ionic Zn and Cu in the
aggregation of b-amyloid (Ab) in Alzheimer’s disease.3,8 However,
the ubiquity of trace metals (Fe, Cu and Zn in particular) in the cell,
as well as the relatively weak intermolecular forces governingmetal–
protein ligands presents an analytical challenge to achieving separa-
tion and detection of physiologically-relevant species.9–11 Only frac-
tionation of complex biological mixtures, usually via chromato-
graphic separation, can provide clues as to whether changes in
metal levels observed in neurological tissues are global or confined
to a particular protein, and this protocol must ensure that metal–
protein ligands are preserved. Lelie et al.12 recently used such an
approach to show that Cu,Zn-superoxide dismutase (SOD-1) metal-
lation status, specifically the absence of Cu, was an identifying
feature of familial amyotrophic lateral sclerosis (ALS).
Here, we employed native separation using size exclusion
chromatography (SEC) hyphenated to ICP-MS for detection of
metal cofactors according to molecular weight of the eluting
biomolecules. Coupling SEC to elemental detection itself is not
a new analytical technique; the first featured examples, reported
in the 1980s, used atomic absorption13 and atomic emission
spectrometry14 to detect trace metals in various biological fluids.
Since then, a number of examples of SEC hyphenated to mass
specific detection have been used to study trace metals in a
variety of physiological and disease states, including rat serum,15
cancerous human thyroid tissue,16 murine neurological tissue17
and platinum-treated human blood products18 to name just a
few. Common themes to these foundation papers are lengthy
runtimes and diﬃculties in acquiring truly quantitative data.
Using standard metalloproteins, we were able to absolutely
quantify the metal content of each eluting species, and have
suggested the possible biological molecules associated with
specific metal ions. We present a method that is well suited to
high throughput analysis of biological samples relevant to the
emerging field of metalloproteomics19 using minimal sample
volumes and rapid chromatographic separations.
Experimental
Chemicals and standards
SOD-1 (Cu,Zn) and ferritin (Fe; Sigma Aldrich, Castle Hill, Australia)
protein standards were used for metal quantification. Ammonium
nitrate buﬀers were prepared fresh daily using MiliQ (18.2 MO)
H2O. All samples undergoing solution ICP-MS analysis for bulk
metal content were diluted to volume in 1% (v/v) Suprapur HNO3.
SEC column calibration was performed using molecular weight
standards for ferritin (MW = 450 kDa), ceruloplasmin (MW =
151 kDa), conalbumin (MW = 75 kDa; GE Healthcare, Rydal-
mere, Australia), SOD-1 (MW = 32 kDa (dimer)) and metallothio-
nein IIa (MW = 6.5 kDa).
Liquid chromatography-inductively coupled plasma-mass
spectrometry
We used an Agilent Technologies 1200 liquid chromatography
system (Mulgrave, Australia) with the eluent directly inserted into
a standard perfluoroalkoxy (PFA) concentric design nebuliser via
polyethyl ether ketone (PEEK) tubing (o.d. 1.58 mm; i.d. 0.13 mm).
The nebuliser was fitted to an Agilent Technologies 7700x ICP-MS.
Helium was used as a collision gas to remove polyatomic inter-
ferences. Separations were performed on an Agilent Technologies
Bio-SEC 3 size exclusion column (3 mm particle size; 150 Å pore
structure; 4.6 mm i.d.) with a 200 mM ammonium nitrate buﬀer
(pH 7.7–7.8). The ICP-MS was tuned daily using solution nebulisa-
tion of a 1 mg L1 Li, Co, Y, Ce and Tl standard. Typical operating
parameters of the SEC-ICP-MS system are given in Table 1.
External calibration
SOD-1 and ferritin standards were prepared fresh prior to
analysis. Standards were reconstituted in 0.1 M phosphate
Table 1 Typical operational SEC-ICP-MS parameters
Agilent 1200 LC
Mobile phase 0.2 M NH4NO3 (pH 7.7–7.8)
Column type Agilent Bio-SEC 3
Particle size 3 mm
Pore size 150 Å
Flow rate mL min1
Injection volume 1–100 mL (100 mg total protein)
Column dimensions 4.6 mm (i.d.)  150 mm
Agilent 7700x ICP-MS
RF power 1550 W
Sample depth 8.0 mm
Carrier gas 0.95 L min1
Makeup gas 0.20 L min1
Spray chamber temperature 7 1C
Extracts 1, 2 12, 200 V
Omega bias, lens 95, 8.3 V
Deflect, plate bias 2.2, 60 V
Cell entrance, exit 38, 68 V
Octopole bias, RF 18.0, 200 V
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buﬀered saline (PBS) and total metal content was determined by
bulk ICP-MS analysis. Total metal loading on column was
controlled by varying the injection volume from 3 to 75 mL.
The area under baseline-corrected peaks was integrated using
Prism 5 (GraphPad, La Jolla, USA) and used to construct multi-
point calibration curves for each measured mass. Linear regres-
sion analysis was used to convert signal intensity (counts
per second) to picogram of metal per second.
Primary cell cultures
Primary murine culture protocols were approved by the University of
Melbourne Biosciences Animal Ethics Committee (approval number
1011753.4). For primary cortical cultures, E14 mouse cortices were
removed, dissected free of meninges and dissociated in 0.025%
trypsin. Viable dissociated cells were suspended inMinimumEagle’s
Medium supplemented with 10% fetal bovine serum, 5% horse
serum, 1% glutamine, and 10 mg mL1 gentamicin, plated into poly-
L-lysine coated 6 well culture plates (1.5  106 cells per well), and
incubated at 37 1C in 5% CO2. Growth medium was replaced with
Neurobasal growth medium supplemented with 2% B27, 1% gluta-
mine and 10 mg mL1 gentamicin the following day. 3–4 days after
plating, half of themedia was replaced with freshNeurobasalmedia.
Cells were used for experiments 6 days after plating.
For astrocyte cultures, neonatal mice were decapitated and
whole brains were removed and placed into ice-cold prepara-
tion buﬀer (containing 8 g L1 NaCl, 400 mg L1 KCl, 30 mg L1
KH2PO4, 24 mg L
1 Na2HPO4, 20 g L
1 sucrose, 1 g L1 glucose,
200 U mL1 penicillin and 200 mg mL1 streptomycin). Brains
were sequentially passed through 250 mm and 135 mm gauze
and centrifuged at 500 g for 5 min. Cell pellets were resus-
pended in growth medium (high glucose DMEM containing
10% fetal bovine serum, 50 U mL1 penicillin and 50 mg mL1
streptomycin) and plated in 6 well plates at 1.5  106 cells per
well. Cells were maintained at 37 1C with 10% CO2. Growth
medium was replaced at 7 and 14 days, and experiments were
performed after 16 days in vitro.
Sample preparation and analysis
Pellets of cultured neurons and astrocytes were resuspended in
Tris-buﬀered saline (TBS; 50 mM Tris, 150 mM NaCl; pH 8.0)
with added EDTA-free protease inhibitors (Roche, Castle Hill,
Australia) and homogenized by 6 passes through a 26-gauge
needle. The homogenate was then centrifuged at 13 200g for
5 minutes and the supernatant recovered. Injection volumes
were standardised according to total protein content (UV
absorbance at 280 nm) of the sample (ca. 10 mg mL1) measured
by a NanoDrop spectrophotometer (ThermoFisher Scientific,
Victoria, Australia). Samples were kept at 4 1C prior to injection
using a Peltier-cooled autosampler. Each injection contained
approximately 100 mg of total protein.
Results and discussion
Analytical performance
External calibration using multiple injections of metalloproteins
standards enabled us to quantify both the total metal content in
individual SEC-ICP-MS separations and the eluting metal
concentration in pg s1.20 Injection volumes ranged from 3 to
75 mL, for eﬀective loading of 6–150 ng of Fe and 0.6–15 ng of
Cu and Zn, which was in turn used to perform external calibration
by linear regression with good linearity (r2 > 0.999) for the three
measured masses (Fig. 1a–c). Limits of analysis were determined
using 3s for limit of detection (LOD) and 10s for limit of quanti-
fication (LOQ) for total metal loaded on column. For Fe, LOD and
LOQ were 0.825  0.005 ng and 2.75  0.02 ng, respectively,
equivalent to 14.8  0.1 pmoles and 49.2  0.4 pmoles. Cu and Zn
returned LOD and LOQ values of 130 22 pg (2.05  0.35 pmoles)
and 433  74 pg (6.81  1.16 pmoles); and 13.6  0.7 pg (0.21 
0.01 pmoles) and 45.6  2.4 pg (0.70  0.04 pmoles), respectively.
Repeated injections of 20 ng Fe (as ferritin) and 2.0 ng Cu and
Zn (as SOD-1) (n = 4) returned coefficients of variation of 1.28%,
7.26%, and 2.40%. Calibration of the SEC column using Fe-,
Cu- and Zn-binding metalloproteins returned good linearity for
unknown molecular weight determination (Fig. 1d).
This quantitative SEC-ICP-MS method is well suited to high
throughput analysis. The smaller column diameter (4.6 mm)
than previous SEC-ICP-MS methods allows for smaller injection
volumes (1–100 mL per injection) while maintaining sensitivity
and reduced turnaround time per sample (o15 min).
Quantification of metal content of neurons and astrocytes
Chromatograms for each measured mass were normalised to
the total peak area of the 280 nm absorbance trace (in addition
to pre-injection standardisation using absorbance at 280 nm
measured by UV-Vis spectroscopy), and thereby total protein
content to confirm equivalent mass loading onto the SEC
column. The total peak area for each measured mass was used
to determine the total metal loading on column, and thus the
concentration of metal in the homogenate per 1 mg of total
protein loaded (Table 2). This approach allows for both speciation
of metalloproteins and assay of the total metal content of cells.
Interestingly, the total Fe content of both neuronal and astrocytic
cultures was lower than Cu and Zn, even though Fe is generally
at a higher concentration in brain tissue,21 suggesting that
either high brain Fe is sourced from other cell types, such as
Fe-rich oligodendrocytes,22 or that typical cell culturing condi-
tions are Fe-deficient. In fact, we have previously observed that
increase in astrocyte uptake of free Fe in metal-enriched (as ferric
ammonium citrate; FAC) was as much as 20-fold,23 while cellular
uptake of ionic Cu and Zn was minimal.24,25 The Fe content of
both cell types was comparable to previously reported values
using alternative quantitative techniques, such as the ferrozine-
based colourimetric assay26 and atomic absorption spectro-
scopy.27 Similarly, the Cu content of astrocytes28 and neurons29
was also analogous to previous reports, as was the basal level of
Zn in both cell types compared to other cell culture studies.30,31
In general, astrocytes contained a greater concentration of both
Fe and Zn than neurons, while neurons contained around twice
the Cu concentration to that of astrocytes.
The method presented here demonstrates several significant
advances in LC-ICP-MS separation and detection. Quantifica-
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collected fractions,32 which further weakens the already poor
separation resolution experienced with native SEC separation.
Online quantification via flow-injection calibration of standard
metalloproteins allows for determination of the amount of
metal eluting from the column on a per-point basis. The half-peak
width of moderately abundant metalloproteins was typically
around 20 s, equivalent to approximately 14 points per peak.
Integration of the area under curve (AUC) for each peak can
feasibly be used to quantify total metal loading on species-
specific metalloproteins, adding to available options including
quantification via isotope-dilution ICP-MS.33–35
Diversity in metalloproteins between cell types
Neurons and astrocytes predictably display a diverse range of
metalloprotein species (Fig. 2 and 3). The Fe-binding species
of neurons and astrocytes were generally comparable, with
major Fe-containing peaks observed at approximately Ve/V0
(ratio of elution volume to void) = 1.55 (MW = 450 kDa) and
Ve/V0 = 1.84 (MW = 80 kDa), as well as low mass species eluting
after the total column volume (VT; MWo 0.5 kDa). As expected,
the majority of Fe in both cell types is likely associated with
high molecular weight ferritin (Ve/V0 = 1.55;MW = 450 kDa), and
astrocytes were observed to contain as much as 10 times more
ferritin-bound Fe than neurons. Ferritin is ubiquitously expressed
in both neurons and astrocytes, the amount of which diﬀers
depending on both brain region36 and Fe homeostatic require-
ments.37 The peak at Ve/V0 = 1.84 (MW = 80 kDa) is likely to be
indicative of the major Fe-transport protein transferrin.
Ceruloplasmin (Cp; Ve/V0 = 1.74; MW 151 kDa) accounts for
over 90% of circulating Cu and plays a major role in brain
Fe metabolism.38 Interestingly, this protein was observed almost
exclusively in neurons (see Fig. 2). Immunohistochemical studies
of Cp in brain sections has previously identified expression in
both cell types,39 and it is unclear as to why cultured astrocytes
do not display a Cu peak corresponding to Cp. A variety of
Cu-binding proteins and peptides have been identified in
astrocytes, including transporters (Copper transporter receptor
1 – Ctr1; divalent metal transporter 1 – DMT1; ATP7A), intra-
cellular traffickers (SOD-1, copper chaperone for superoxide
dismutase – CSS; ATOX1, Cox17), and storage and detoxifiers
(metallothioneins – MTs).40 Both cell types, though more
pronounced in astrocytes, showed colocalised Cu and Zn peaks,
reflective of SOD-1 homodimer (see Fig. 3) at Ve/V0 = 2.02 (MW =
32 kDa). A common Cu-binding protein is observed in both cell
Table 2 Fe, Cu and Zn concentration (per mg total protein) in neuron and
astrocyte cultures
Neurons (n = 4) Astrocytes (n = 5)
ng mg1 nmol mg1 ng mg1 nmol mg1
Fe 7.31  0.90a 0.131  0.016a 27.7  2.0a 0.497  0.037a
Cu 200  30 3.15  0.47 105  9 1.66  0.14
Zn 29.1  3.8 0.445  0.058 47.7  3.3 0.730  0.050
a Below limit of quantification, indication only.
Fig. 1 External calibration procedure for (a) Fe, (b) Cu and (c) Zn by SEC-ICP-MS. Total metal injected onto the SEC column was controlled by increasing the injection
volume of a known metalloprotein standard (ferritin for Fe; SOD-1 for Cu and Zn). Integration of the total area under curve (AUC) for each injection was used to
perform linear regression analysis against the total metal injected, allowing conversion of ICP-MS signal output to pg s1. (d) SEC column was calibrated using ferritin
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types at Ve/V0 = 2.26 (MW = 6 kDa) that may be attributable to
either MTIIa (per the standard protein) or small cuproproteins,
such as Cox17 and ATOX1.41 An extremely small peak is
observed in astrocytes at Ve/V0 = 1.71 (MW = 178 kDa) may be
indicative of Ctr1.28
The Zn profile in both cell types was generally similar, with
the exception of a major Zn binding protein at Ve/V0 = 2.32
(MW = 4.1 kDa) in astrocytes not identified in neurons. A similar
Cu-containing peak at Ve/V0 = 2.36 (MW = 3.2 kDa) is also
observed in astrocytes. These peaks are thought to represent
Fig. 2 (a) UV absorbance trace (280 nm), (b) Fe, (c) Cu and (d) Zn chromatograms from neuron (red line) and astrocyte (blue line) cultures. Dashed line = 1 standard
deviation, n = 4 (neurons) and n = 5 (astrocytes). Black arrow denotes Cu-binding Cp (Ve/V0 = 1.74).
Fig. 3 Overlay of normalised Fe, Cu and Zn traces for cultured neurons (left) and astrocytes (right). Inset: Cu and Zn peak at Ve/V0 = 2.02 in astrocytes corresponds to
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astrocytic expression of MT isoforms, which are high aﬃnity Zn
(and Cu) binders expressed in this cell type that play an
important role in the response to neuronal injury.42–44 In situ
hybridization, radioimmunoassay and immunohistochemistry
has previously identified MT-I and -II expression in glia and
ependymal cell cultures.45
Growth conditions of both cell types may influence the metal-
loprotein profile. Neurons were grown in serum-free Neurobasal
medium (following an initial period on serum-containing media),
whilst astrocytes were grown in 10% fetal bovine serum. This
diﬀerence may account for diﬀering protein expression, though
this also reflects the diﬀerent extracellular environments each cell
type would maintain in vivo. Regardless, growing either cell type in
a consistent serum-rich or serum-free environment would only
serve to produce unviable cells, which would undoubtedly produce
an artificial aﬀect on protein diversity. This approach has greater
utility in studying the cellular response to metal dyshomeostasis:
further work will examine shifts in metalloprotein species
following the addition of bioavailable metals. However, a
possible avenue of investigation could use a transient/separable
co-culture system (reviewed by Miki et al.46) in order to expose
cells to the same growth media.
Global versus targeted metalloproteomics
The typical approach to metalloprotein analysis can best be
described as a targeted method, where specific purification and
sample cleanup steps precede direct measurement of a known
species via electrospray MS, such as metallation status of SOD-1
in ALS spinal cord tissue47,48 and heavy metal-bindingMT isoforms
in hepatic and renal tissue49–51 (see Eve Roberts’ review52 for a
comprehensive synopsis of targeted metalloproteomic strategies
from the perspective of hepatic disorders). The approach described
here provides a ‘global’ evaluation for comparative biology
across a broad mass range, which allows for rapid identifi-
cation of either generalised metal deficiency (as we observed
with respect to Fe) or changes in a specific metal-binding peak,
which may be a candidate for a more targeted metalloproteomic
assay. For specific conditions, such as familial ALS where metalla-
tion status of the abundant metalloenzyme is impaired, this
approach provides not only sufficient native chromatographic
resolution to isolate SOD-1, but also provides an accurate
quantification method that can be related to protein–metal
stoichiometry. As such, this rapid quantitative technique has
the potential to play an important role in the study of disorders
involving impairment to metal metabolism.
Conclusions
Primary cultures of murine neurons and astrocytes contain a
wide range of metalloproteins, which can be quantified with
relative simplicity using native SEC hyphenated to ICP-MS and
a range of metalloprotein standards. Native chromatography
allows direct detection of metal cofactors in a non-denaturing
environment, ensuring that the relatively weak interactions typical
of protein–metal complexes are preserved. Online quantitative
SEC-ICP-MS extends the capabilities of hyphenated techniques
to allow direct detection and quantification of metal cofactors,
thus allowing meaningful biological comparison of the role of
the metalloproteome in health and disease.
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